Prostate tumors, resistant to current antiandrogen therapies, represent a serious clinical challenge. A new report identifies androgen-receptor-dependent liquid condensates as being responsible in part for therapeutic resistance, but, encouragingly, also reveals a novel vulnerability amenable to drug targeting.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wang, B. et al. Signal Transduct. Target. Ther. 6, 290 (2021).
Stortz, M., Presman, D. M., Pecci, A., Levi, V. & Ruggieri, A. Biochem J. 478, 443–461 (2021).
Xie, J. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-022-01151-y (2022).
McEwan, I. J. Mol. Biosyst. 8, 82–90 (2012).
Asangani, I. et al. J. Biol. Chem. 296, 100240 (2021).
Bouchard, J. J. et al. Mol. Cell 72, 19–36 (2018).
Bielskutė, S. et al. Protein Sci. 30, 1427–1437 (2021).
Ahmed, J., Meszaros, A., Lazar, T. & Tompa, P. Protein Sci. 30, 1380–1392 (2021).
Andersen, R. J. et al. Cancer Cell 17, 535–546 (2010).
Ruggieri, A. & Stoecklin, G. Nat. Chem. Biol. 15, 5–6 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
McEwan, I.J. Breaking apart condensates. Nat Chem Biol 18, 1292–1293 (2022). https://doi.org/10.1038/s41589-022-01161-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-022-01161-w